Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.06. | QUIA PHARMA AB (publ) receives observation status | 134 | GlobeNewswire | On June 5, 2025, QUIA PHARMA AB (publ) (the "Company") disclosed its annual financial report for 2024 with information on the Company's financial situation.
The rules of Nasdaq First North... ► Artikel lesen | |
QUIA PHARMA Aktie jetzt für 0€ handeln | |||||
04.04. | Decision by the Disciplinary Committee regarding QUIA PHARMA AB (publ) | 313 | GlobeNewswire | Stockholm, April 4, 2025- The Disciplinary Committee of Nasdaq Stockholm (the "Exchange") has found that QUIA PHARMA AB (publ) (the "Company") has breached the rules of Nasdaq First North Growth... ► Artikel lesen | |
17.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.02.2025 | 1.292 | Xetra Newsboard | Das Instrument 99B0 SE0020678159 QUIA PHARMA AB O.N. EQUITY wird cum Kapitalmassnahme gehandelt am 17.02.2025 und ex Kapitalmassnahme am 18.02.2025 The instrument 99B0 SE0020678159 QUIA PHARMA AB O.N.... ► Artikel lesen | |
23.01. | Nasdaq Stockholm AB: QUIA PHARMA AB (publ) receives observation status | 298 | GlobeNewswire | On November 25, 2024, QUIA PHARMA AB (publ) (the "Company") disclosed a press release with information that the Company had received a Statement of Reprimand from Nasdaq Stockholm AB expressing the... ► Artikel lesen | |
20.08.24 | Nasdaq Stockholm AB: Change of company name: QuiaPEG Pharmaceuticals Holding AB changes name to QUIA PHARMA AB (publ) | 411 | GlobeNewswire | As from August 21, 2024, QuiaPEG Pharmaceuticals Holding AB will change company
name to QUIA PHARMA AB (publ). ISIN Code and Ticker will not change.
Old company name: QuiaPEG Pharmaceuticals Holding... ► Artikel lesen | |
14.08.24 | Nasdaq Stockholm AB: The observation status for QuiaPEG Pharmaceuticals Holding AB (publ) is removed | 408 | GlobeNewswire | On March 16, 2023, QuiaPEG Pharmaceuticals Holding AB (publ) (the "Company")
was given observation status with reference to material adverse uncertainty in
respect of the Company's financial position.... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,965 | -0,29 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
EVOTEC | 7,286 | -0,22 % | Aktienmarkt: Evotec-Aktie tritt auf der Stelle (7,232 €) | Im deutschen Wertpapierhandel ist das Wertpapier von Evotec aktuell unauffällig. Der jüngste Kurs betrug 7,23 Euro. Wenig getan hat sich heute bislang beim Kurs von Evotec. Mit einem Preis von 7,23... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 28,335 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
BIONTECH | 96,55 | +1,21 % | BioNTech-Konkurrent Moderna: Aktie mit Kurssprung - was ist da los? | Die Aktie von Moderna hat am Dienstag einen kräftigen Kurssprung hinlegen können. Das Papier ging als Top-Gewinner des Tages im S&P 500 vor Intel und Albemarle aus dem Handel. Moderna notiert nun so... ► Artikel lesen | |
DYNE THERAPEUTICS | 9,330 | 0,00 % | Dyne shares up after CEO buys stock | ||
AVIDITY BIOSCIENCES | 33,510 | +5,64 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
CRISPR THERAPEUTICS | 47,600 | +4,85 % | Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS | ||
MODERNA | 26,995 | -1,62 % | Moderna's latest approval again reveals FDA rift over COVID vaccines | ||
RECURSION PHARMACEUTICALS | 5,390 | 0,00 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
VOR BIOPHARMA | 2,150 | 0,00 % | Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer | Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass.,... ► Artikel lesen | |
PRIME MEDICINE | 4,040 | 0,00 % | Prime Medicine sichert sich bis zu 24 Millionen US-Dollar Zusatzfinanzierung von Mukoviszidose-Stiftung | ||
ADMA BIOLOGICS | 17,670 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
PROKIDNEY | 3,745 | 0,00 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen | |
BEAM THERAPEUTICS | 20,070 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
CUREVAC | 4,694 | +0,43 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen |